发明名称 |
FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO |
摘要 |
Disclosed are prodrugs of therapeutic or imaging agents, which prodrugs are selectively cleaved by fibroblast activating protein (FAP) to release the agents. Upon cleavage by FAP of the FAP substrate, the prodrug releases the agent in its active form or in a form that is readily metabolized to its active form. Pharmaceutical compositions comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation are also disclosed. |
申请公布号 |
US2017119901(A1) |
申请公布日期 |
2017.05.04 |
申请号 |
US201515318627 |
申请日期 |
2015.06.15 |
申请人 |
TRUSTEES OF TUFTS COLLEGE |
发明人 |
Bachovchin William W.;Lai Hung-sen;Sanford David G.;Poplawski Sarah E.;Wu Wengen |
分类号 |
A61K38/00;A61K31/7068;A61K31/4375;A61K31/4155;A61K31/519;A61K31/517;A61K31/337;A61K31/69;A61K31/704;A61K31/4545 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A prodrug for fibroblast activation protein (FAP)-dependent release of an agent, comprising a FAP substrate covalently linked to an agent via a bond or a self-immolative linker; wherein:
the agent is a drug; upon cleavage by FAP of the FAP substrate, the prodrug releases the agent in its active form or in a form that is readily metabolized to its active form; the prodrug has less than 50% of the therapeutic activity of the active form of the agent; and the FAP substrate has a kcat/Km for cleavage by FAP at least 10-fold greater than for cleavage by prolyl endopeptidase (EC 3.4.21.26; PREP). |
地址 |
Boston MA US |